Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06622486 | First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 50 | Egle TherapeuticsINDUSTRY | 2 | Nov 7, 2024 | clinicaltrials |
| NCT06410703 | CAN1012 Combined With PD-1 in Patients With Solid Tumors | unknown | Phase 1 / Phase 2 | 71 | Canwell Biotech LimitedINDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors |
| terminated |
| Phase 1 / Phase 2 |
| 39 |
| BeiGeneINDUSTRY |
| 3 |
| Oct 26, 2024 |
| clinicaltrials |
| NCT04068519 | Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody | completed | Phase 1 / Phase 2 | 300 | BeiGeneINDUSTRY | 1 | Oct 26, 2024 | clinicaltrials |
| NCT05522582 | Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors | active not recruiting | Phase 2 | 50 | Yancheng First People's HospitalOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03486730 | BT1718 in Patients with Advanced Solid Tumours. | completed | Phase 1 / Phase 2 | 72 | Cancer Research UKOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT04690699 | LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors | terminated | Phase 1 / Phase 2 | 4 | Istari Oncology, Inc.INDUSTRY | 1 | Oct 24, 2024 | clinicaltrials |
| NCT04492488 | A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer | active not recruiting | Phase 1 / Phase 2 | 129 | Shanghai Miracogen Inc.INDUSTRY | 1 | Oct 22, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT03592264 | A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 68 | OBI Pharma, IncINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | terminated | Phase 1 / Phase 2 | 13 | BioNTech SEINDUSTRY | 2 | Oct 2, 2024 | clinicaltrials |
| NCT06322095 | A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors | unknown | Phase 2 | 72 | Suzhou Genhouse Bio Co., Ltd.OTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT05765032 | Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 220 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06413615 | A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors | unknown | Phase 2 | 150 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2024 | clinicaltrials |
| NCT04205227 | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 137 | ENB Therapeutics, IncINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT04434482 | IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 59 | Impact Therapeutics, Inc.INDUSTRY | 5 | Sep 19, 2024 | clinicaltrials |
| NCT04474470 | A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer | completed | Phase 1 / Phase 2 | 52 | TyrNovo Ltd.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT04721223 | JAB-3068 Activity in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 12 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05367778 | Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 176 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06525298 | EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors | recruiting | Phase 1 / Phase 2 | 144 | Eisbach Bio GmbHINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06551051 | ADC-induced Neurotoxicity Treated With Duloxetine | recruiting | Phase 2 | 37 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05824455 | A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 4 | Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.INDUSTRY | 1 | Sep 5, 2024 | clinicaltrials |
| NCT03473925 | Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | completed | Phase 2 | 107 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Aug 28, 2024 | clinicaltrials |
| NCT00791154 | QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer(SCLC) | terminated | Phase 1 / Phase 2 | 213 | NantCell, Inc.INDUSTRY | 0 | Aug 23, 2024 | clinicaltrials |
| NCT06185556 | COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases(COLDFIRE-III) | recruiting | Phase 2 / Phase 3 | 78 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT06224387 | CTS2190 Phase I /II Clinical Study in Patients | unknown | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT04185831 | A MolEcularly Guided Anti-Cancer Drug Off-Label Trial(MEGALiT) | unknown | Phase 2 | 167 | Uppsala University HospitalOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT04770207 | Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | terminated | Phase 1 / Phase 2 | 89 | NantCell, Inc.INDUSTRY | 0 | Aug 20, 2024 | clinicaltrials |
| NCT04946864 | A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer | suspended | Phase 1 / Phase 2 | 65 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 19, 2024 | clinicaltrials |
| NCT04770688 | Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib(AUTOMAN) | completed | Phase 1 / Phase 2 | 25 | Shanghai Chest HospitalOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT03658785 | Immunotherapy for the Treatment of Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 40 | Tongji HospitalOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT04282031 | A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer | unknown | Phase 1 / Phase 2 | 224 | Beta Pharma (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT04121442 | Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 15 | Buzzard PharmaceuticalsINDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06537505 | A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors | not yet recruiting | Phase 2 | 60 | Beidahuang Industry Group General HospitalOTHER | 0 | Aug 5, 2024 | clinicaltrials |
| NCT03852251 | A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma | completed | Phase 1 / Phase 2 | 338 | AkesoINDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06531486 | A Study of XS-02 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 96 | NovaOnco Therapeutics Co., Ltd.INDUSTRY | 0 | Aug 1, 2024 | clinicaltrials |
| NCT01283945 | Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 134 | Institut de Recherches Internationales ServierOTHER | 3 | Jul 25, 2024 | clinicaltrials |
| NCT04393454 | Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy | terminated | Phase 2 | 6 | Albert Einstein College of MedicineOTHER | 1 | Jul 25, 2024 | clinicaltrials |
| NCT06519110 | Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations(CVL009-C2001) | unknown | Phase 2 | 60 | Convalife (Shanghai) Co., Ltd.INDUSTRY | 0 | Jul 25, 2024 | clinicaltrials |
| NCT04570839 | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | completed | Phase 1 / Phase 2 | 48 | Compugen LtdINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT03320330 | Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 26 | Children's Oncology GroupNETWORK | 1 | Jul 15, 2024 | clinicaltrials |
| NCT05159245 | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs(FINPROVE) | recruiting | Phase 2 | 250 | Helsinki University Central HospitalOTHER | 1 | Jul 15, 2024 | clinicaltrials |
| NCT03802123 | ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors(iCorrelate) | completed | Phase 2 | 52 | ImaginAb, Inc.INDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT05880043 | GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies | unknown | Phase 1 / Phase 2 | 50 | GI Cell, Inc.INDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06490068 | Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy | unknown | Phase 2 | 10 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06439589 | Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 88 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT04111107 | Precision Medicine for Patients With Identified Actionable Mutations | terminated | Phase 2 | 45 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 7, 2024source: clinicaltrials